Move Over Xanax? New Research on LSD Offers Hope for Anxiety

Move over Xanax, Prozac, and Duloxetine? A recent study comparing a single oral dose of MM120 (LSD) with a placebo suggests that LSD may be an effective treatment for anxiety. More recently, Definium Therapeutics (August 12, 2026) announced positive topline results from its Phase III VOYAGE trial of DT120, a formulation of LSD, for generalized anxiety disorder. The findings have not yet undergone peer review or full scientific publication.

Lysergic acid diethylamide, or LSD, was first synthesized by Swiss chemist Albert Hofmann in 1938. The pharmaceutical company Sandoz marketed LSD in 1947 as Delysid, promoting it for treating schizophrenia and depression, as well as a tool for exploring consciousness.

Harvard psychologist Timothy Leary and others promoted its use but came under fire for unscientific and unethical experiments. The unregulated and often irresponsible drug usage linked LSD with dangerous behavior.

In 1968, the federal government classified LSD as a Schedule I illegal substance, dramatically limiting legal access. More recently, non-medical hallucinogen use has been increasing, as has emergency care.

Could LSD Treat Anxiety? What the New Study Found

In the study, co-authored by Massachusetts General Hospital's Psychiatrist-in-Chief Maurizio Fava, M.D., single administration of higher-dose LSD produced robust and sustained reductions in anxiety symptoms lasting an astonishing 12 weeks. Only subjects receiving the two highest doses showed significant clinical improvement, indicating the observed efficacy was unlikely due to expectancy bias (finding what one hopes to find).

Patients in the study well-tolerated LSD, though initial psychedelic effects required direct observation on the day of administration. Participants were continuously monitored during dosing by supportive individuals who provided music/eyes-shades and basic assistance, but no therapy.

The study findings encouraged psychedelic researchers that LSD appears on track for Phase 3 studies and ultimately for LSD to be approved for treating generalized anxiety disorder (GAD). Pre-clinical work suggests psychedelics may promote neuroplasticity and openness of brain networks, thus decreasing anxiety.

In a JAMA editorial on this research, Claudio N. Soares, M.D., Ph.D., asks whether "psychedelic agents are ready for prime time as stand-alone treatments," calling the trial an important contribution but also noting unanswered questions and methodological challenges. Adverse events in the study were mostly transient effects expected with LSD (perceptual changes, nausea, headache), which may increase with dose.

News coverage noted that many participants correctly guessed whether they received LSD or the placebo. After the 2024 FDA rejection of MDMA for PTSD over methodology and bias concerns, many experts expect there will be high evidentiary bars and scrutiny before any psychedelic approval occurs.

Charles B. Nemeroff, M.D., Ph.D., of the Dell Medical School at the University of Texas at Austin, told me: "The randomized controlled clinical studies of LSD in patients with generalized anxiety disorder reveal a remarkable and long-lasting effect of a single dose (100 or 200 μg) compared to lower doses and placebo, with few side effects. Earlier studies in Europe found similar effects on anxiety and depression. These were conducted in safe clinical research settings with very rigorous inclusion and exclusion criteria and should not be generalized to non-medically supervised LSD use outside such settings.”

A systematic review of LSD (and other psychedelics) for anxiety disorders noted LSD decreased anxiety ratings and had positive psychological effects, such as increased mental strength, in small studies.

Generalized Anxiety Disorder Is Common

GAD is a common psychiatric illness, with a lifetime prevalence of 5-8 percent of the population. It also frequently co-occurs with depression, other anxiety disorders, and substance abuse.

The course of GAD is often chronic and relapsing, with the probability of relapsing after remission of nearly a third (27 percent) of patients by three years and more than a third (about 38 percent) at five years. Many patients don’t respond adequately to first-line treatments, and others don’t respond at all. So, there is a substantial unmet need for GAD treatments.

Today, the most commonly used first-line medications in GAD are antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Benzodiazepine medications are effective at treating GAD (especially in the short-term), but concerns about dependence, tolerance, cognitive/functional side-effects, and limited long-term data generally restrict their use for GAD long-term.

Anxiety Essential Reads

When Someone Else's Tragedy Becomes Your Fear

Studies Point to the Most Effective Ways to Treat Social Anxiety Disorder

Combined treatment (medication + psychotherapy) often yields better outcomes in moderate-to-severe cases of anxiety for individuals who partially respond. Nevertheless, even with combined treatment, many patients have residual anxiety, and may relapse.

The sizeable subset of patients with GAD continuing to struggle has encouraged psychiatrists to explore novel approaches. LSD is one of these.

More Options Needed for Treatment-Resistant GAD

If it is approved by the FDA, LSD might be an option for what is known as treatment-resistant GAD. "Treatment-resistant" often refers to either a non-response or a partial response to first-line treatments. One review estimated that approximately 30 to 60 percent of treated anxiety disorder patients have an insufficient response.

Yet the last new medication approval by the Food and Drug Administration (FDA) for generalized anxiety disorder (GAD) occurred in 2007, when a delayed‐release form of duloxetine received an indication for GAD. Current GAD treatments typically require daily dosing and may cause persistent adverse effects like sexual dysfunction.

In contrast, a single LSD administration may produce transient side effects, but it may also provide long-term benefits of relief from anxiety. Earlier LSD-assisted therapy studies (in other anxiety settings, such as anxiety in a life-threatening illness) have shown sustained reductions in anxiety and comorbid depression up to 12 months post-treatment.

What LSD's FDA Breakthrough Status Means

The FDA has granted breakthrough therapy designation to MindMed’s LSD (MM120) for GAD—a signal that early data may represent a substantial improvement; further studies will receive extra guidance and expedited attention. The data are still early, and regulatory approval has not yet been granted.

If proven safe and effective, LSD could shift the paradigm from "medicate daily for years" to an intensive therapeutic experience + integration" model. If implemented, a treatment delivery infrastructure would also need to be developed, including pre-treatment assessment, risk mitigation, monitoring of the patient during the administration of LSD to manage hallucinations, perceptual changes, and anxiety during dosing, as well as provide therapist support and integration sessions.

Final Thoughts on LSD and Anxiety

It's important to emphasize that LSD is neither approved by the FDA nor yet a standard of care in the treatment of GAD; the evidence is promising but preliminary. Yet despite these caveats, it appears at long last, there may be new hope on the horizon for patients with debilitating anxiety.